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Behavioral Interactions of Opioid
Agonists and Antagonists With
Serotonergic Systems
Richard H. Rech, David J. Mokler,
Randall L. Commissaris, and Judith W. Henck
Morphine interacts with brain serotonergic (5-HT) systems; these systems
have been implicated in morphine analgesia and dependence see Cervo et
al., 1981). The 5-HT agonist quipazine induces analgesia in rats that is
attenuated by naloxone and 5-HT antagonists (Minnema et al., 1980;
Samanin et al., 1976). Behavioral disruption by the hallucinogens LSD,
DMT and mescaline, mediated primarily through brain 5-HT effects (Rech
and Commissaris, 1982), is potentiated by naloxone and naltrexone (Com-
missaris et al., 1980; Ruffing and Domino, 1981) and is variably antago-
nized or potentiated by morphine and methadone (Ruffing and Domino,
1981). Cyclazocine causes a disruption of operant behavior similar to that
of the hallucinogens which is reversed in part by naloxone and the 5-HT
antagonist metergoline, and to a greater extent by the combination of
naloxone and metergoline (Henck et al., 1983). These studies indicate
that indole and phenethylamine hallucinogens interact to some extent
with brain opioid mechanisms as well as brain 5-HT components, whereas
opioid drugs influence behavior in part by actions on 5-HT systems.
We have extended these drug studies in an attempt to characterize
interactions with 5-HT mechanisms and to identify the various types of
opioid receptors involved.
METHODS
Male Sprague-Dawley rats were food deprived to 75-80% of free-feeding
weights and trained to a fixed ratio-40 (FR-40) schedule of food rein-
forcement. The number of reinforcers (Bioserve 45 mg food pellets) and
“pause intervals” (a 10 sec period without a response, Commissaris et al.,
1980; Rech and Commissaris, 1982) were recorded for daily 40-min
sessions. Changes in the patterns of responding were determined after
combinations of lysergic acid diethylamide (LSD) or 2,5-dimethoxy-4-
methylamphetamine (DOM) with naloxone (NAL), cyclazocine (CYCL)
with quipazine (QUIP) or metergoline (MTG), ethylketocyclazocine (EKC)
with NAL or MTG, and N-allyl-normetazocine (SKF 10,047; SKF) with
NAL or MTG. Dose-response curves were analyzed by a one-way ANOVA
using the least significant differences (lsd) test for comparing individual
doses to baseline; multiple dose-response curves were compared by a two-
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way ANOVA using the lsd test for individual comparisons. The signifi-
cance level was set at p< 0.05.
RESULTS
LSD (12.5-100 µg/kg) or DOM (0.125-1.0 mg/kg) caused a dose-related
increase in pause intervals (Fig. 1) that was reciprocally related to a
decrease in reinforcers delivered. Pretreatment with 4 mg/kg NAL
potentiated the disruptive effects of LSD and DOM, but neither dose-
response curve was shifted in a parallel fashion.
CYCL disrupted FR-40 responding as shown in Fig. 2. Like the hallucino
gens, CYCL caused a dose-related decrease in reinforcers that was
reciprocally related to increases in pausing. This disruption was attenu-
ated over the entire dose range, at least for pauses, by pretreating with a
low dose of QUIP (0.5 mg/kg). Additional pretreatment with MTG (1.0
mg/kg) nullified the QUIP antagonism only at the highest dose of CYCL
tested. A previous report indicated that the CYCL effects were
antagonized over the middle-dose range by both NAL (4 mg/kg) and MTG
(1 mg/kg) pretreatment, and combination of these pretreatments showed
additive protection (Henck et al., 1983).
FR-40 disruption was also observed with QUIP (Fig. 3) and a dose-related
reciprocal increase in pausing was again associated with the decrease in
reinforcers. Therefore, the hallucinogens, certain opioids, and 5-HT
agonists appear to affect FR-40 responding in this manner. Pretreatment
with NAL (4 mg/kg) slightly potentiated the disruptive effects of low
doses of QUIP but had no significant effect at higher doses. Likewise,
pretreatment with a small dose of CYCL (0.5 mg/kg) slightly potentiated
low dose QUIP without influencing the effect of higher doses. However,
when the NAL and CYCL pretreatments were combined, the marked
disruption observed after 2.0 mg/kg QUIP. alone was greatly attenuated.
Thus, the disruptive effects of QUIP may involve both 5-HT and opioid
mechanisms.
The prototype kappa agonist EKC (Fig. 4) decreased reinforcers in a dose-
related manner with a reciprocal increase in pauses, but, unlike the
hallucinogens, exhibited a steep dose-response curve. Pretreatment with
NAL slightly potentiated the disruptive effects of low doses of EKC but
prominently antagonized the effects of higher doses. Pretreatment with
MTG also enhanced the effects of low doses of EKC and antagonized EKC
disruption only at the 1.0 mg/kg dose. A low dose (0.5 mg/kg) of CYCL
was also administered as a pretreatment (not illustrated) and interacted
with EKC in a pattern very similar to that noted with MTG pretreatment.
Since SKF has hallucinogenic properties and may be a selective agonist at
sigma receptors, its effects on the FR-40 operant pattern were examined
(Fig. 5). Once more the hallucinogenic profile of decreased reinforcers
with a reciprocal increase in pause intervals was obtained. In this case
pretreatment with 4 mg/kg NAL did not significantly influence the
disruptive pattern of the drug. Pretreatment with MTG slightly antago
nized the effects of SKF at several intermediate doses. Therefore, SKF
does not appear to exert these disruptive effects via NAL-sensitive opioid
receptors, but may act to some extent through 5-HT mechanisms.
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with 4 mg/kg naloxone (NAL) (closed circles) on FR-40 behavioral
response pattern.
Fig. 1. Dose-response of LSD or DOM alone (open circles) or combined
Fig.  2 .  Dose-response of
cyclazocine (CYCL) alone,
Fig. 3. Dose-response of quipazine
combined with 0.5 mg/kg
(QUIP) alone, combined with 4 mg/kg
quipazine (QUIP), or com-
naloxone (NAL), with 0.5 mg/kg cycla-
bined with 0.5 mg/kg QUIF’
zocine (CYCL), or with both NAL and
CYCL.
and 1.0 mg/kg metergoline
(MTG ) .
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Pretreating with a low dose (0.5 mg/kg) of CYCL (results not illustrated)
slightly attenuated the increase in pausing at the highest dose (16 mg/kg)
of SKF, but otherwise had no appreciable effect.
Fig. 4. Dose-response of
ethylketocyclazocine (EKC)
alone, combined with 4
mg/kg naloxone (NAL), or
combined with 1 mg/kg me-
tergoline (MTG).
DISCUSSION
Fig. 5. Dose-response of
SKF 10,047 (SKF) alone, combined
with 4 mg/kg naloxone (NAL), or
combined with 1 mg/kg meter-
goline (MTG).
The shifts of the dose-response curves of LSD, DOM (Fig. 1 and
mescaline (Commissaris et al., 1980) to the left by pretreatment with 4
mg/kg NAL were not parallel, suggesting that the opioid interaction is
modulatory and not exerted at the same receptors as those affected by
the hallucinogens. Similar results were found for LSD and DMT by
Ruffing and Domino (1981). Additionally, they observed antagonism of
the operant behavioral disruption of hallucinogens by pretreating with low
doses of morphine or methadone. The dose of NAL required to produce
these interactions (2-8 mg/kg) is in the range optimal for kappa receptor
antagonism rather than that which is optimal for mu antagonism (0.2-1.0
mg/kg).
Disruption of the FR-40 operant pattern by these hallucinogenic drugs is
characterized by dose-related decreases in responses (reinforcers earned)
correlated with increases in pause intervals (10-sec intervals without a
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response) over the entire dose-response curve (Rech and Commissaris,
1982). This pattern of impairment is not observed with many other
psychoactive drugs (chlorpromazine, d-amphetamine, pentobarbital), but
is seen with other 5-HT agonists, such-as QUIP and lisuride. The operant
behavioral effects of hallucinogens and non-hallucinogenic 5-HT agonists
are attenuated by pretreating with MTG and other 5-HT antagonists, but
the rate-decreasing effect of the other classes of psychoactive agents is
not affected by these pretreatments. However, the opioid mixed agonist-
antagonist CYCL was found to disrupt the FR-40 operant pattern in the
same way as the hallucinogens did, i.e., a decrease in reinforcers
correlated with a reciprocal increase in pause intervals (Henck et al.,
1983). Furthermore, this impairment was partly antagonized by pretreat-
ing with NAL, MTG, or a combination of the two.
The behavioral effects of CYCL were attenuated by a low dose of QUIP
(Fig. 2). This antagonism may relate in part to the opioid-like effects of
QUIP (Minnema et al., 1980; Samanin et al., 1976). However, 5-HT
influences may also pertain, since combined pretreatment with QUIP and
MTG reversed the protection by QUIP at the higher doses of CYCL. QUIP
itself, at higher dose levels, caused a decrement in FR-40 responding (Fig.
3), which was little affected by pretreatment with NAL or a low dose of
CYCL. Nevertheless, the combined pretreatment with NAL and CYCL
reversed both the decrease in reinforcers and the increase in pausing
caused by the 2 mg/kg dose of QUIP. It seems likely that both opioid and
5-HT mechanisms are involved in this complex interaction.
If the CYCL effects on FR-40 behavior act in part through kappa opioid
receptors, the more selective kappa agonist EKC might show similar
effects. However, interactions of EKC with NAL or MTG were quite
complex (Fig. 4). The slight potentiation of lower doses of EKC by NAL
may relate to subtle opioid influences at other than kappa receptors. The
prominent protection by NAL against higher doses of EKC probably does
involve kappa receptors. The fact that MTG pretreatment enhanced the
disruptive effects of low doses of EKC but attenuated those from a higher
dose suggests that EKC interacts in a complex manner with 5-HT
mechanisms that influence this behavior.
Lastly, the actions of SKF (Fig. 5) must be mediated via mechanisms
different from those involved in the effects of indole and phenethylamine
hallucinogens and QUIP and CYCL. NAL had no effect on the SKF dose-
response pattern in keeping with a mechanism involving sigma receptors,
which are considered NAL-insensitive (Simon and Hiller, 19781 MTG
pretreatment exerted only a slight protection against the behavioral
decrement caused by SKF, indicating that the latter drug does not act
primarily via 5-HT receptors.
The results of this study show that the opioids CYCL and EKC produce
their disruption of operant behavior by interacting, at least in part, with
5-HT and NAL-sensitive opioid systems. Thus, they appear to exert their
effects in a manner related to the actions of indole and phenethylamine
hallucinogens. On the contrary, the effects of SKF appear to be mediated
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